Drug General Information (ID: DDI95GS4Q3)
Drug Name			Inotuzumab ozogamicin		Drug Info		Rucaparib		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Poly (Adp-Ribose) Polymerase Inhibitors

Mechanism of Inotuzumab ozogamicin-Rucaparib Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Inotuzumab ozogamicin				Rucaparib
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Rucaparib

Recommended Action
Management		Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use cannot be avoided or if inotuzumab ozogamicin is used in patients with other risk factors for QT prolongation. The manufacturer suggests obtaining electrocardiograms and serum electrolytes at baseline and regularly during treatment.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Besponsa (inotuzumab ozogamicin). Wyeth Laboratories, Philadelphia, PA.